Longeveron (LGVN) Stock News

Longeveron announced positive Phase 1 study results of Lomecel-B for treating Alzheimer's disease and completed two Phase 2 trials evaluating its safety and efficacy in Aging Frailty subjects. Top-line results from these studies are expected in Q3 2021. The CEO, Geoff Green, will present at the Benzinga Global Small Cap Conference on May 13-14, 2021, highlighting the company's clinical research efforts, including aging-related conditions. Longeveron aims to advance Lomecel-B towards regulatory approval and commercialization.

Longeveron Inc. (NASDAQ: LGVN) has been selected to present at the 2021 World Stem Cell Summit from June 14-18. Dr. Joshua Hare, Chief Science Officer, will discuss the Longevity Agenda and present findings on Lomecel-B, a therapy targeting aging-related conditions like Alzheimer's and Aging Frailty. The company anticipates sharing results from clinical trials in the third quarter. Geoff Green, CEO, expressed pride in participating in this prestigious event, emphasizing the promise of cell-based therapies in improving healthspan.

Longeveron has completed a Phase I/II clinical study evaluating Lomecel-B's effectiveness in enhancing immune response to the flu vaccine in elderly individuals with aging frailty. Funded partially by the Maryland Technology Development Corporation and the National Institute on Aging, the study involved randomized, double-blinded trials at seven centers in Florida and Maryland. Results are expected in Q3 2021, revealing Lomecel-B's potential to mitigate inflammation and improve B cell function for better vaccine response in this vulnerable population.

Longeveron Inc. (NASDAQ: LGVN) announced positive final results from its Phase 1 clinical trial of Lomecel-B for treating mild Alzheimer’s disease. The study met its primary safety endpoint and showed that cognitive decline was slower in patients receiving low-dose Lomecel-B compared to placebo. Notably, quality of life metrics improved, with significant differences at 26 weeks. Complete trial results will be published soon. The company is poised to initiate a Phase 2 study in the latter half of 2021, indicating a proactive approach towards potential Alzheimer's treatments.

Longeveron Inc. (NASDAQ: LGVN) reported its financial results for Q4 and full year 2020, highlighting a net loss of $1.4 million for Q4 compared to $0.5 million in Q4 2019. Revenue was $1.2 million in Q4 2020, down from $1.8 million in Q4 2019, primarily due to decreased grant revenue. However, revenue from the Bahamas Registry Trial increased by 119% year-over-year. The company secured a $29.1 million IPO and anticipates sufficient cash to support operations through Q4 2022. Upcoming results from multiple clinical trials are expected in 2021.

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company, announced a conference call on March 30, 2021, at 8:30 a.m. ET to discuss its fiscal 2020 financial results and provide a business update. The call will be accessible via telephone and a webcast. Longeveron is focused on developing cellular therapies for chronic aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, targeting multiple indications including Aging Frailty and Alzheimer’s disease. An audio replay of the call will be available until April 6, 2021.

MIAMI, March 19, 2021 – Longeveron (NASDAQ: LGVN), a biotechnology company focused on cellular therapies for aging-related and life-threatening conditions, will present at the Q1 Virtual Investor Summit. The event runs from March 23-25, 2021, with Longeveron's presentation scheduled for March 24 at 10:00 am ET. This summit connects smallcap companies with investors, featuring over 100 companies and 300 investors. Longeveron is advancing its lead therapy, LOMECEL-B, aimed at conditions like Aging Frailty and Alzheimer’s disease. For more details, visit longeveron.com.

Longeveron Inc. (NASDAQ:LGVN) announced the partial exercise of its over-allotment option by underwriters in its IPO, increasing total shares sold to 2,910,000 at a public offering price of $10.00. This results in gross proceeds of $29.1 million before offering expenses. The SEC had previously declared effective a registration statement for these securities on February 11, 2021. Longeveron is focused on developing cell-based therapies for aging-related conditions and is sponsoring clinical trials for several serious health issues.

Longeveron Inc. (NASDAQ: LGVN) received FDA approval for expanded access to its investigational cell therapy, Lomecel-B, for a child with Hypoplastic Left Heart Syndrome (HLHS). The therapy aims to enhance the right ventricle's function, which is crucial for HLHS patients. Dr. Sunjay Kaushal of Ann & Robert H. Lurie Children’s Hospital will administer the treatment during surgery. Lomecel-B is derived from bone marrow and produced in Miami. The company successfully completed a Phase 1 study demonstrating safety, leading to a Phase 2 trial set for Q3 2021, progressing towards regulatory approval.